Bergavit (Citrus bergamia extract)

Bergavit is a standardized Citrus bergamia (bergamot orange) extract concentrated in polyphenolic flavonoids—primarily brutieridin and melitidin—that inhibit HMG-CoA reductase, the same enzyme targeted by statin drugs. Clinical evidence shows it meaningfully reduces LDL and total cholesterol while raising HDL in adults with elevated baseline lipid levels.

Origin & History

Bergavit is a proprietary standardized extract from the fruit of Citrus bergamia (bergamot), a citrus plant native to the coastal Calabrian region of Italy. It is produced by Bionap (Italy) using water/ethanol extraction from bergamot juice at a 150:1 ratio, yielding a powder rich in flavonoids standardized to 25-28% content.

Historical & Cultural Context

No specific historical or traditional medicinal uses were detailed for Bergavit or bergamot in the available research. Modern applications focus exclusively on its flavonoid-rich composition for cardiovascular support.

Health Benefits

• Reduces LDL cholesterol by 11.5% based on a 4-month study with 80 subjects (preliminary evidence)
• Lowers total cholesterol by 8.8% in individuals with elevated LDL-C levels (>130 mg/dL)
• Increases HDL cholesterol by 5.5% (trending toward significance in clinical studies)
• Reduces oxidized LDL by 2.0%, potentially supporting cardiovascular health
• Increases PON1 enzyme activity by 6.5%, which may protect against LDL oxidation

How It Works

Bergavit's primary bioactives, brutieridin and melitidin, contain a statin-like moiety that competitively inhibits HMG-CoA reductase, thereby reducing hepatic cholesterol biosynthesis. Additionally, bergamot flavonoids including naringenin and neoeriocitrin activate AMPK (AMP-activated protein kinase), upregulating LDL receptor expression on hepatocytes to enhance LDL clearance from circulation. Oxidized LDL reduction is attributed partly to the direct free-radical scavenging capacity of these polyphenols, lowering lipoprotein susceptibility to oxidative modification.

Scientific Research

A 4-month prospective interventional study with 80 subjects with high LDL-C (>130 mg/dL) tested 375 mg/day Bergavit, showing significant reductions in total cholesterol, LDL-C, and oxidized LDL (PMC11641072). European clinical studies support its role in healthy lipid metabolism, though specific designs and additional PMIDs are not detailed in available data.

Clinical Summary

A 4-month randomized clinical study in 80 subjects with elevated LDL-C (>130 mg/dL) found Bergavit supplementation reduced LDL cholesterol by 11.5%, total cholesterol by 8.8%, and increased HDL by 5.5%, though the HDL finding trended toward rather than reaching statistical significance. The extract also demonstrated reductions in oxidized LDL, a marker of cardiovascular oxidative stress. Evidence is preliminary given the modest sample size and single study design; larger, multicenter randomized controlled trials are needed to confirm these findings. Current data is promising but should not be considered equivalent to the robust evidence base supporting pharmaceutical statins.

Nutritional Profile

Bergavit is a standardized extract derived from Citrus bergamia (bergamot orange) fruit, primarily composed of bioactive polyphenolic flavonoids. Key bioactive compounds include: brutieridin and melitidin (statin-like flavonoids, present at standardized concentrations typically 25–40% total polyphenols), naringenin, neoeriocitrin, neohesperidin, and narirutin. Total polyphenol content is standardized to approximately 38–40% w/w in commercial Bergavit 40® preparations. Flavanone glycosides constitute the dominant polyphenol class, with brutieridin and melitidin being unique to bergamot and notable for their HMG-CoA reductase inhibitory activity (mechanistically analogous to statins). Hydroxycinnamic acids (e.g., ferulic acid, caffeic acid) are present in minor concentrations (<5%). Bergamot juice also contains vitamin C (ascorbic acid) in the whole fruit, but extract concentrations vary by processing method and are not standardized in Bergavit. Fiber content is negligible in the concentrated extract form. Protein and fat content are trace (<1% each). Bioavailability notes: flavanone glycosides require hydrolysis by gut microbiota to aglycone forms (naringenin, hesperetin) prior to intestinal absorption; bioavailability is moderate (~15–30% of ingested flavanones), enhanced when taken with food. The unique structural features of brutieridin and melitidin may confer direct enzyme inhibition independent of full systemic absorption.

Preparation & Dosage

Clinically studied dosage: 375 mg/day Bergavit powder in capsule form, standardized to 150 mg flavonoids (neohesperidin, naringin, neoeriocitrin). This corresponds to 550-600 mg/day for equivalent flavonoid intake. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Red yeast rice, plant sterols, niacin, omega-3 fatty acids, artichoke leaf extract

Safety & Interactions

Bergavit is generally well tolerated at studied doses, with no serious adverse events reported in the 4-month clinical trial; mild gastrointestinal discomfort is the most commonly noted side effect. Because brutieridin and melitidin share a mechanism with HMG-CoA reductase inhibitors, combining Bergavit with prescription statins may produce additive lipid-lowering effects and warrants physician supervision to monitor for myopathy or excessive LDL reduction. Bergamot compounds may interact with CYP3A4-metabolized drugs—including certain statins, calcium channel blockers, and immunosuppressants—potentially altering their plasma concentrations. Safety data during pregnancy and lactation is insufficient, so use is not recommended in those populations without medical guidance.